Donna L White1, Fasiha Kanwal, Hashem B El-Serag. 1. Clinical Epidemiology and Outcomes Program, Houston Veteran Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, USA. dwhite1@bcm.edu
Abstract
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) has been implicated as a cause of hepatocellular carcinoma (HCC). We performed a systematic review of epidemiology studies to confirm the association between these disorders. METHODS: We searched PubMed for original reports published from January 1992 to December 2011 that evaluated the association between NAFLD, nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis presumed to be NASH-related, and the risk of HCC. Studies were categorized as offering potential direct evidence (eg, cohort studies) or indirect evidence (eg, case-control, cross-sectional, or case-series studies) for an association. We analyzed data from a total of 17 cohort studies (3 population based, 9 clinic based [6 limited to patients with cirrhosis], and 5 natural history), 18 case-control and cross-sectional studies, and 26 case series. RESULTS: NAFLD or NASH cohorts with few or no cases of cirrhosis cases had a minimal risk for HCC (cumulative HCC mortality of 0%-3% for study periods up to 20 y). Cohorts with NASH and cirrhosis had a consistently higher risk (cumulative incidence ranging from 2.4% over 7 y to 12.8% over 3 y). However, the risk for HCC was substantially lower in these cohorts than for cohorts with hepatitis C-related cirrhosis. Factors that increased risk among cohorts with NASH and cirrhosis could not be determined, because most studies were not sufficiently powered for multivariate analysis. CONCLUSIONS: This systematic review shows that despite several limitations, there is epidemiologic evidence to support an association between NAFLD or NASH and an increased risk of HCC; risk seems to be limited to individuals with cirrhosis.
BACKGROUND & AIMS:Nonalcoholic fatty liver disease (NAFLD) has been implicated as a cause of hepatocellular carcinoma (HCC). We performed a systematic review of epidemiology studies to confirm the association between these disorders. METHODS: We searched PubMed for original reports published from January 1992 to December 2011 that evaluated the association between NAFLD, nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis presumed to be NASH-related, and the risk of HCC. Studies were categorized as offering potential direct evidence (eg, cohort studies) or indirect evidence (eg, case-control, cross-sectional, or case-series studies) for an association. We analyzed data from a total of 17 cohort studies (3 population based, 9 clinic based [6 limited to patients with cirrhosis], and 5 natural history), 18 case-control and cross-sectional studies, and 26 case series. RESULTS: NAFLD or NASH cohorts with few or no cases of cirrhosis cases had a minimal risk for HCC (cumulative HCC mortality of 0%-3% for study periods up to 20 y). Cohorts with NASH and cirrhosis had a consistently higher risk (cumulative incidence ranging from 2.4% over 7 y to 12.8% over 3 y). However, the risk for HCC was substantially lower in these cohorts than for cohorts with hepatitis C-related cirrhosis. Factors that increased risk among cohorts with NASH and cirrhosis could not be determined, because most studies were not sufficiently powered for multivariate analysis. CONCLUSIONS: This systematic review shows that despite several limitations, there is epidemiologic evidence to support an association between NAFLD or NASH and an increased risk of HCC; risk seems to be limited to individuals with cirrhosis.
Authors: Rachel E Bullock; Abed M Zaitoun; Guruprasad P Aithal; Stephen D Ryder; Ian J Beckingham; Dileep N Lobo Journal: J Hepatol Date: 2004-10 Impact factor: 25.083
Authors: Eun Ju Cho; Min Sun Kwack; Eun Sun Jang; Su Jong You; Jeong-Hoon Lee; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee Journal: Digestion Date: 2011-12-02 Impact factor: 3.216
Authors: Helma P Cotrim; Edison R Parise; Claudia P M S Oliveira; Natalhie Leite; Ana Martinelli; João Galizzi; Rita de Cássia Silva; Angelo Mattos; Leila Pereira; Waldir Amorim; Claúdia Ivantes; Francisco Souza; Marcelo Costa; Lizomar Maia; Mário Pessoa; Frederico Oliveira Journal: Ann Hepatol Date: 2011 Jan-Mar Impact factor: 2.400
Authors: M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal Journal: Aliment Pharmacol Ther Date: 2016-01-19 Impact factor: 8.171
Authors: Jie Yan; Yang Yu; Jeon Woong Kang; Zhi Yang Tam; Shuoyu Xu; Eliza Li Shan Fong; Surya Pratap Singh; Ziwei Song; Lisa Tucker-Kellogg; Peter T C So; Hanry Yu Journal: J Biophotonics Date: 2017-06-21 Impact factor: 3.207
Authors: Melanie Kahle; Marion Horsch; Barbara Fridrich; Anett Seelig; Jürgen Schultheiß; Jörn Leonhardt; Martin Irmler; Johannes Beckers; Birgit Rathkolb; Eckhard Wolf; Nicole Franke; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susanne Neschen Journal: Mol Metab Date: 2013-08-03 Impact factor: 7.422
Authors: Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh Journal: Br J Radiol Date: 2018-08-29 Impact factor: 3.039
Authors: Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon Journal: Cancer Prev Res (Phila) Date: 2016-08-29